Breaking News Instant updates and real-time market news.

REGN

Regeneron

$351.27

-29.44 (-7.73%)

07:18
10/25/18
10/25
07:18
10/25/18
07:18

Regeneron reports Phase 3 PANORAMA trial met primary endpoint

Regeneron Pharmaceuticals announced that the Phase 3 PANORAMA trial evaluating EYLEA Injection in patients with moderately severe and severe non-proliferative diabetic retinopathy met its one-year primary endpoint and key secondary endpoints. On the primary endpoint at one year, 80% and 65% of patients receiving EYLEA on an every 8- and every 16-week interval, after an initial monthly dosing period, respectively, experienced a two-step or greater improvement from baseline on the Diabetic Retinopathy Severity Scale, compared to 15% of patients receiving sham injection. Regarding the two key secondary endpoints, which achieved statistical significance based on the pre-specified hierarchical analysis, treatment with EYLEA also reduced vision-threatening complications by 82%-85% and the development of center-involved diabetic macular edema by 68%-74% compared with sham injection. George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, said, "In this trial of patients with diabetic eye disease and normal vision, it is notable that without treatment more than one third of patients developed a vision-threatening complication or diabetic macular edema within one year. EYLEA was able to reduce these complications by 68%-85% even with every four-month dosing, and moreover was able to reverse the anatomic severity of the disease. These results point to the potential value of earlier intervention in diabetic retinopathy and may in the future change the way retina specialists treat this disease."

  • 28

    Oct

  • 06

    Nov

  • 28

    Apr

  • 13

    May

REGN Regeneron
$351.27

-29.44 (-7.73%)

10/16/18
LEER
10/16/18
NO CHANGE
LEER
Outperform
Regeneron data won't derail Intersect ENT's Sinuva, says Leerink
Leerink analyst Richard Newitter attributes the underperformance today in shares of Intersect ENT (XENT) to Regeneron's (REGN) positive Phase 3 Dupixent data for chronic rhinosinusitis with nasal polyps. The Dupixent readout had always represented a potential headline risk for Intersect ENT during Q4, Newitter tells investors in a research note. The analyst, however, thinks it's better to get the headline out of the way before a J-code decision in early November. Further, based on physician feedback around monoclonal antibodies, Newitter does not get the sense that these therapies will "necessarily derail" adoption of Intersect ENT's Sinuva or its total addressable market. The analyst continues to believe in-line Q3 results will be a "win" for Intersect ENT and he keeps an Outperform rating on the shares. The stock in afternoon trading is down 68c to $29.24.
10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.
10/22/18
PIPR
10/22/18
NO CHANGE
Target $450
PIPR
Overweight
Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says that while Regeneron Pharmaceuticals' asthma label for Dupixent does not broadly cover patients regardless of eosinophilic phenotype as he had anticipated, it does cover oral corticosteroid dependent patients regardless of eosinophilic phenotype, which essentially matches his modeling. Moreover, the analyst notes that the label covers all patients 12 and older, and both moderate and severe disease. As such, he sees the label as broad, "but not necessarily as anticipated." The analyst is making no change to his numbers based on the label and keeps an Overweight rating on Regeneron with a $450 price target.
10/22/18
CANT
10/22/18
NO CHANGE
Target $441
CANT
Neutral
Regeneron price target raised to $441 from $419 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Regeneron Pharmaceuticals to $441 citing Dupixent's label in asthma, which she thinks is broad. The analyst believes the shares could trade up 5% on the label but she keeps a Neutral rating on the name. Dupixent expectations are high already, Young tells investors in a research note.

TODAY'S FREE FLY STORIES

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

18:39
05/22/19
05/22
18:39
05/22/19
18:39
Periodicals
Breaking Periodicals news story on Daiichi Sankyo »

Daiichi Sankyo in talks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SPOT

Spotify

$127.10

-5.06 (-3.83%)

18:27
05/22/19
05/22
18:27
05/22/19
18:27
Periodicals
Spotify resets some users' passwords over 'suspicious activity,' TechCrunch says »

Spotify has informed an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDXX

Idexx Laboratories

$250.45

1.24 (0.50%)

18:20
05/22/19
05/22
18:20
05/22/19
18:20
Hot Stocks
Idexx Laboratories CEO: We're at the beginning of our runway for growth »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

OMC

Omnicom

$79.79

-0.3 (-0.37%)

18:15
05/22/19
05/22
18:15
05/22/19
18:15
Hot Stocks
Omnicom CEO sells 60.5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$37.74

0.04 (0.11%)

18:12
05/22/19
05/22
18:12
05/22/19
18:12
Hot Stocks
Boston Scientific initiates trial of WATCHMAN FLX appendage closure platform »

Boston Scientific has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 26

    Jun

  • 13

    Nov

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:03
05/22/19
05/22
18:03
05/22/19
18:03
Hot Stocks
Ctrip reports Q1 gross margin 79% vs. 82% a year ago »

Remained consistent with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:02
05/22/19
05/22
18:02
05/22/19
18:02
Earnings
Breaking Earnings news story on Ctrip »

Ctrip sees Q2 net revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTRP

Ctrip

$37.63

-0.24 (-0.63%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Earnings
Ctrip reports Q1 adjusted EPS 44c, consensus 24c »

Reports Q1 revenue $1.2B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CE

Celanese

$100.10

-0.18 (-0.18%)

18:01
05/22/19
05/22
18:01
05/22/19
18:01
Hot Stocks
Celanese announces acetyls product price increases »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRAY

Dentsply Sirona

$54.64

-0.25 (-0.46%)

17:57
05/22/19
05/22
17:57
05/22/19
17:57
Hot Stocks
Dentsply Sirona CFO Alexos to leave company in connection with relocation »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 05

    Jun

SIM

Grupo Simec

$9.23

(0.00%)

17:55
05/22/19
05/22
17:55
05/22/19
17:55
Hot Stocks
Grupo Simec receives noncompliance notification from NYSE »

Grupo Simec announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$64.78

-1.12 (-1.70%)

17:51
05/22/19
05/22
17:51
05/22/19
17:51
Earnings
Copart reports Q3 adjusted EPS 66c, consensus 62c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 03

    Jun

NVS

Novartis

$83.94

1.555 (1.89%)

17:51
05/22/19
05/22
17:51
05/22/19
17:51
Periodicals
Novartis CEO sees Zolgensma price 'far lower' than $4M-$5M range, Reuters says »

Novartis CEO Vas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 31

    May

PCG

PG&E

$19.00

0.55 (2.98%)

17:45
05/22/19
05/22
17:45
05/22/19
17:45
Periodicals
PG&E to remain in control of bankruptcy until September 29, WSJ reports »

PG&E will remain in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

OBLN

Obalon Therapeutics

$1.24

0.842 (211.56%)

17:41
05/22/19
05/22
17:41
05/22/19
17:41
Hot Stocks
Obalon Therapeutics discloses resignation of CEO »

In a regulatory 8-K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GVA

Granite Construction

$41.37

-0.09 (-0.22%)

17:39
05/22/19
05/22
17:39
05/22/19
17:39
Hot Stocks
Granite Construction acquires additional trenchless rehabilitation assets »

Granite Construction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

NVCN

Neovasc

$0.48

-0.0023 (-0.48%)

17:36
05/22/19
05/22
17:36
05/22/19
17:36
Hot Stocks
Neovasc discloses International Journal of Cardiology review of Neovasc Reducer »

Neovasc announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.61

-0.89 (-0.31%)

17:36
05/22/19
05/22
17:36
05/22/19
17:36
Periodicals
Pentagon mulls request to send 5,000 U.S. troops to Middle East, Reuters says »

The U.S. Department of…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.61

-0.89 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POOL

Pool Corp.

$183.36

-0.52 (-0.28%)

17:35
05/22/19
05/22
17:35
05/22/19
17:35
Hot Stocks
Pool Corp. Chairman John Stokely sells almost $2M in company shares »

Pool Corp. Chairman John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 18

    Jun

  • 13

    Nov

RTN

Raytheon

$180.57

-2.05 (-1.12%)

17:35
05/22/19
05/22
17:35
05/22/19
17:35
Hot Stocks
Raytheon awarded $151.47M Navy contract for AIM-9X missile sustainment »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

ESV

Ensco Rowan

$10.01

-0.365 (-3.52%)

17:31
05/22/19
05/22
17:31
05/22/19
17:31
Hot Stocks
Ensco Rowan says will not pay a regular quarterly cash dividend »

Ensco Rowan announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$171.29

1.67 (0.98%)

, GILD

Gilead

$66.51

-0.01 (-0.02%)

17:30
05/22/19
05/22
17:30
05/22/19
17:30
Upgrade
Amgen, Gilead, Alexion, Vertex, BioMarin, Biogen, Regeneron rating change  »

Citi assumes coverage of…

AMGN

Amgen

$171.29

1.67 (0.98%)

GILD

Gilead

$66.51

-0.01 (-0.02%)

ALXN

Alexion

$127.47

-1.33 (-1.03%)

VRTX

Vertex

$172.37

3.22 (1.90%)

BMRN

BioMarin

$87.80

0.33 (0.38%)

BIIB

Biogen

$234.98

2.04 (0.88%)

REGN

Regeneron

$320.00

10.19 (3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 28

    Jun

BBX

BBX Capital

$4.95

-0.06 (-1.20%)

, BXG

Bluegreen Vacations

$14.91

-0.2 (-1.32%)

17:24
05/22/19
05/22
17:24
05/22/19
17:24
Hot Stocks
BBX Capital says will not proceed with merger with Bluegreen Vacations »

BBX Capital (BBX)…

BBX

BBX Capital

$4.95

-0.06 (-1.20%)

BXG

Bluegreen Vacations

$14.91

-0.2 (-1.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

RTN

Raytheon

$180.57

-2.05 (-1.12%)

17:21
05/22/19
05/22
17:21
05/22/19
17:21
Hot Stocks
Raytheon awarded $234.64M Navy contract »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

WEX

Wex

$203.30

-1.56 (-0.76%)

17:20
05/22/19
05/22
17:20
05/22/19
17:20
Hot Stocks
Wex CEO sells 5K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.